These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37370255)

  • 1. Neoantigens in cancer immunotherapy: quantity vs. quality.
    Wolf Y; Sameuls Y
    Mol Oncol; 2023 Aug; 17(8):1457-1459. PubMed ID: 37370255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
    Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
    De Mattos-Arruda L; Vazquez M; Finotello F; Lepore R; Porta E; Hundal J; Amengual-Rigo P; Ng CKY; Valencia A; Carrillo J; Chan TA; Guallar V; McGranahan N; Blanco J; Griffith M
    Ann Oncol; 2020 Aug; 31(8):978-990. PubMed ID: 32610166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy targeting neoantigens.
    Lu YC; Robbins PF
    Semin Immunol; 2016 Feb; 28(1):22-7. PubMed ID: 26653770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigens: promising targets for cancer therapy.
    Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L
    Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
    Okada M; Shimizu K; Fujii SI
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sources of Cancer Neoantigens beyond Single-Nucleotide Variants.
    Capietto AH; Hoshyar R; Delamarre L
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
    Lu T; Wang S; Xu L; Zhou Q; Singla N; Gao J; Manna S; Pop L; Xie Z; Chen M; Luke JJ; Brugarolas J; Hannan R; Wang T
    Sci Immunol; 2020 Feb; 5(44):. PubMed ID: 32086382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoantigens in precision cancer immunotherapy: from identification to clinical applications.
    Zhang Q; Jia Q; Zhang J; Zhu B
    Chin Med J (Engl); 2022 Jun; 135(11):1285-1298. PubMed ID: 35838545
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Zhang Z; Zhou C; Tang L; Gong Y; Wei Z; Zhang G; Wang F; Liu Q; Yu J
    Aging (Albany NY); 2020 Jul; 12(14):14633-14648. PubMed ID: 32697765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor neoantigens: from basic research to clinical applications.
    Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
    J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoantigen: A New Breakthrough in Tumor Immunotherapy.
    Zhang Z; Lu M; Qin Y; Gao W; Tao L; Su W; Zhong J
    Front Immunol; 2021; 12():672356. PubMed ID: 33936118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A proteogenomic approach to target neoantigens in solid tumors.
    Verma A; Halder A; Marathe S; Purwar R; Srivastava S
    Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoantigens and their clinical applications in human gastrointestinal cancers.
    Eshkiki ZS; Agah S; Tabaeian SP; Sedaghat M; Dana F; Talebi A; Akbari A
    World J Surg Oncol; 2022 Sep; 20(1):321. PubMed ID: 36171610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene fusion neoantigens: Emerging targets for cancer immunotherapy.
    Wang Y; Shi T; Song X; Liu B; Wei J
    Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.
    Kiyotani K; Chan HT; Nakamura Y
    Cancer Sci; 2018 Mar; 109(3):542-549. PubMed ID: 29288513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Identification of neoantigens and development of antigen-specific immunotherapy].
    Shinohara S; Takahashi Y; Demachi-Okamura A; Matsushita H
    Rinsho Ketsueki; 2020; 61(9):1433-1439. PubMed ID: 33162546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
    Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L
    Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized T cell-mediated cancer immunotherapy: progress and challenges.
    Bethune MT; Joglekar AV
    Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.